drugset / Trial / NCT06170294
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2025-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TCR-MAGE-A4 T-Cells | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |